Augmentation Enterocystoplasty: A Critical Review

Smith, Robert B.; Cangh, Paul Van; Skinner, Donald G.; Kaufman, Joseph J.; Goodwin, Willard E.

doi:10.1016/s0022-5347(17)57878-7

Cited by 119 publications

(32 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On average, the patients were followed for 11 (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) months, when both objective and subjective parameters had been prospectively studied. Objective parameters were evaluated by urodynamic examination, imaging methods and laboratory tests.…”

Section: Methodsmentioning

confidence: 99%

“…The results can be evaluated using a number of different parameters, but the evaluation should be performed not earlier than 6 months after the surgery because it takes this long for the tissues to heal and for the augmented bladder to regain its elasticity [17][18][19].…”

Section: Complicationsmentioning

confidence: 99%

“…The bladder capacity increases by 184-295% after surgery and reaches 1500 ml in most cases [3,4,19]. The detrusor pressure is usually reduced from the risk values (140 cm H 2 O) to the values of 15-18 (H 2 O) [3,19].…”

Section: Complicationsmentioning

confidence: 99%

“…The detrusor pressure is usually reduced from the risk values (140 cm H 2 O) to the values of 15-18 (H 2 O) [3,19]. A regression of uninhibited contractions has been reported in up to 100% of patients after surgery [5].…”

Section: Complicationsmentioning

confidence: 99%

See 3 more Smart Citations

Augmentation Cystoplasty in Patients with Multiple Sclerosis

Zachoval

Piťha²,

Medova³

et al. 2003

Urol Int

View full text Add to dashboard Cite

Introduction: Augmentation cystoplasty is an effective approach to the detrusor hyperreflexia which is refractory to conservative treatment. Sporadic data have been published in patients with progressive diseases such as multiple sclerosis (MS). Materials and Methods: Augmentation ileocystoplasty (Goodwin ‘cup-patch’) was performed in 9 patients (7 females, 2 males). The average Expanded Disability Status Scale score was 4.1 (range 3.0–6.5); 7 patients had relapse-remitting MS and 2 patients secondary-progressive MS. The indication was a detrusor hyperreflexia refractory to conservative treatment in 8 patients and a detrusor hyperrefluxia with third degree bilateral vesico-ureteral reflux and renal insufficiency in 1 patient. Pre- and postoperative objective parameters were evaluated by urodynamic examination, imaging methods and laboratory examination. Subjective evaluation was performed using a questionnaire on micturition symptoms (score 0–5) and on quality of life (score 0–6). Results: With a follow-up of 6–19 months, we recorded an average increase of the maximum detrusor capacity from 105 to 797 ml and decrease of maximum detrusor pressure from 53 to 30 cm H₂O. Postmicturition residual urine >25% of the maximum capacity was present in 6 patients who performed clear intermittent autocatheterization postoperatively (2 patients preoperatively). In all patients there was a significant improvement in the irritation micturition symptomatology (pollakisuria, nycturia, urgency and urge incontinence) and the quality of life score improved on average from 5 to 0.7. In the case of the patient with renal insufficiency, the creatinine level decreased from 286 to 150 µmol/l; in the other patients renal function remained normal. Conclusions: Augmentation cystoplasty is a safe and effective method for indicated patients, which significantly enhances their quality of life.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Complicationsmentioning

confidence: 99%

Section: Complicationsmentioning

confidence: 99%

Section: Complicationsmentioning

confidence: 99%

See 2 more Smart Citations

Augmentation Cystoplasty in Patients with Multiple Sclerosis

Zachoval

Piťha²,

Medova³

et al. 2003

Urol Int

View full text Add to dashboard Cite

show abstract

“…One must be aware of the potential toxicities that can result from absorption of active drug such as methotrexate or metabolites in patients with augmentation cystoplasty (54) .…”

Section: Drug Absorption Toxicitiesmentioning

confidence: 99%